Atezolizumab Antineoplastic device includes:

  • TECENTRIQ(R)
MS-DRG - Medicare Severity-Diagnosis Related Group
  • MDC 10 Endocrine, Nutritional & Metabolic Diseases & Disorders
    Other Endocrine, Nutritional and Metabolic Procedures
    • DRG 628 - OTHER ENDOCRINE, NUTRITIONAL AND METABOLIC O.R. PROCEDURES WITH MCC
    • DRG 629 - OTHER ENDOCRINE, NUTRITIONAL AND METABOLIC O.R. PROCEDURES WITH CC
    • DRG 630 - OTHER ENDOCRINE, NUTRITIONAL AND METABOLIC O.R. PROCEDURES WITHOUT CC/MCC
  • MDC 99 Other
    Non-extensive Procedure Unrelated to Principal Diagnosis
    • DRG 987 - NON-EXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITH MCC
    • DRG 988 - NON-EXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITH CC
    • DRG 989 - NON-EXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITHOUT CC/MCC

ICD-10-PCS code structure for XW020D8See Table View

1: Section X New Technology
2: Body System W Anatomical Regions
3: Root Operation 0 Introduction
4: Body Part 2 Muscle
5: Approach 0 Open
6: Device D Atezolizumab Antineoplastic
7: Qualifier 8 New Technology Group 8

See also

  • The ICD-10-PCS Index of common procedure terms.
  • New Technology terms in the ICD-10-PCS Definitions table. These definitions may also provide additional explanation and/or examples within this section.
  • The ICD-10-PCS Device Aggregation Table containing entries that correlate a specific ICD-10-PCS device value with a general device value to be used in tables containing only general device values.